Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An update on ketamine and its two enantiomers as rapid-acting antidepressants
Kai Zhang, Kenji Hashimoto
Expert Review of Neurotherapeutics (2018) Vol. 19, Iss. 1, pp. 83-92
Closed Access | Times Cited: 123

Showing 1-25 of 123 citing articles:

Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis
Anees Bahji, Gustavo Vázquez, Carlos A. Zarate
Journal of Affective Disorders (2020) Vol. 278, pp. 542-555
Open Access | Times Cited: 302
Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective
Kenji Hashimoto
Psychiatry and Clinical Neurosciences (2019) Vol. 73, Iss. 10, pp. 613-627
Open Access | Times Cited: 287
Intravenous arketamine for treatment-resistant depression: open-label pilot study
Gustavo C. Leal, Igor D. Bandeira, Fernanda S. Correia‐Melo, et al.
European Archives of Psychiatry and Clinical Neuroscience (2020) Vol. 271, Iss. 3, pp. 577-582
Closed Access | Times Cited: 225
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Jordi Bonaventura, Sherry Lam, Meghan L. Carlton, et al.
Molecular Psychiatry (2021) Vol. 26, Iss. 11, pp. 6704-6722
Open Access | Times Cited: 211
Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine
Kenji Hashimoto
Biochemical Pharmacology (2020) Vol. 177, pp. 113935-113935
Open Access | Times Cited: 193
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei Yan, Lijia Chang, Kenji Hashimoto
Molecular Psychiatry (2021) Vol. 27, Iss. 1, pp. 559-573
Open Access | Times Cited: 184
Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers
Dmitriy Matveychuk, Rejish K. Thomas, Jennifer Swainson, et al.
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 166
Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites
Chun Yang, Jianjun Yang, Ailin Luo, et al.
Translational Psychiatry (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 165
Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine
Wei Yao, Qianqian Cao, Shilin Luo, et al.
Molecular Psychiatry (2021) Vol. 27, Iss. 3, pp. 1618-1629
Open Access | Times Cited: 162
Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine
Lijia Chang, Kai Zhang, Yaoyu Pu, et al.
Pharmacology Biochemistry and Behavior (2019) Vol. 181, pp. 53-59
Closed Access | Times Cited: 151
A historical review of antidepressant effects of ketamine and its enantiomers
Wei Yan, Lijia Chang, Kenji Hashimoto
Pharmacology Biochemistry and Behavior (2020) Vol. 190, pp. 172870-172870
Open Access | Times Cited: 142
Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor
Kenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience (2021) Vol. 271, Iss. 2, pp. 249-258
Open Access | Times Cited: 115
Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability
Sanne Y. Smith-Apeldoorn, Jolien K. E. Veraart, Jan Spijker, et al.
The Lancet Psychiatry (2022) Vol. 9, Iss. 11, pp. 907-921
Open Access | Times Cited: 100
The Neuropsychology of Anxiety
Neil McNaughton, Jeffrey A. Gray
Oxford University Press eBooks (2024)
Closed Access | Times Cited: 73
Esketamine for treatment resistant depression
Jennifer Swainson, Rejish K. Thomas, Shaina Archer, et al.
Expert Review of Neurotherapeutics (2019) Vol. 19, Iss. 10, pp. 899-911
Closed Access | Times Cited: 113
Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1
Kai Zhang, Chun Yang, Lijia Chang, et al.
Translational Psychiatry (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 100
Arketamine, a new rapid-acting antidepressant: A historical review and future directions
Jichun Zhang, Wei Yao, Kenji Hashimoto
Neuropharmacology (2022) Vol. 218, pp. 109219-109219
Open Access | Times Cited: 69
Ketamine and its metabolites: Potential as novel treatments for depression
Kai Zhang, Yitan Yao, Kenji Hashimoto
Neuropharmacology (2022) Vol. 222, pp. 109305-109305
Closed Access | Times Cited: 60
(R)-ketamine ameliorates demyelination and facilitates remyelination in cuprizone-treated mice: A role of gut–microbiota–brain axis
Xingming Wang, Lijia Chang, Xiayun Wan, et al.
Neurobiology of Disease (2022) Vol. 165, pp. 105635-105635
Open Access | Times Cited: 52
Effects of (R)-ketamine on reduced bone mineral density in ovariectomized mice: A role of gut microbiota
Xiayun Wan, Akifumi Eguchi, Yūkō Fujita, et al.
Neuropharmacology (2022) Vol. 213, pp. 109139-109139
Open Access | Times Cited: 44
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
Anees Bahji, Carlos A. Zarate, Gustavo Vázquez
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 6, pp. 853-866
Open Access | Times Cited: 42
(R)-ketamine as prophylactic and therapeutic drug for neurological disorders: Beyond depression
Xingming Wang, Jianjun Yang, Kenji Hashimoto
Neuroscience & Biobehavioral Reviews (2022) Vol. 139, pp. 104762-104762
Open Access | Times Cited: 42
Antioxidant Biomolecules and Their Potential for the Treatment of Difficult-to-Treat Depression and Conventional Treatment-Resistant Depression
María Eugenia Riveros, Alba Ávila, Koen Schruers, et al.
Antioxidants (2022) Vol. 11, Iss. 3, pp. 540-540
Open Access | Times Cited: 41
Mechanistic insights into the potential role of dietary polyphenols and their nanoformulation in the management of Alzheimer’s disease
Hind Muteb Albadrani, Payal Chauhan, Sumel Ashique, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116376-116376
Open Access | Times Cited: 16
(R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders
Hana Shafique, Julie Demers, Julia Biesiada, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6804-6804
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top